Leo S. Choi
Suwon, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Neurotherapeutic effects of Vutiglabridin as a Paraoxonase-2 modulator in preclinical models of Parkinson's disease.
Journal: Molecular neurodegeneration
Published: October 20, 2024
Vutiglabridin Alleviates Cellular Senescence with Metabolic Regulation and Circadian Clock in Human Dermal Fibroblasts.
Journal: Antioxidants (Basel, Switzerland)
Published: December 12, 2023
Paraoxonase-2 agonist vutiglabridin promotes autophagy activation and mitochondrial function to alleviate non-alcoholic steatohepatitis.
Journal: British journal of pharmacology
Published: April 06, 2023
Synthetic Glabridin Derivatives Inhibit LPS-Induced Inflammation via MAPKs and NF-κB Pathways in RAW264.7 Macrophages.
Journal: Molecules (Basel, Switzerland)
Published: January 20, 2023
Vutiglabridin Modulates Paraoxonase 1 and Ameliorates Diet-Induced Obesity in Hyperlipidemic Mice.
Journal: Biomolecules
Published: December 01, 2022
Accelerated aging phenotypes in the retinal pigment epithelium of Zmpste24-deficient mice.
Journal: Biochemical and biophysical research communications
Published: September 09, 2022
Paraoxonase-2 contributes to promoting lipid metabolism and mitochondrial function via autophagy activation.
Journal: Scientific reports
Published: September 08, 2022
Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity.
Journal: International journal of obesity (2005)
Published: March 11, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026